Baili Tianheng (688506.SH): T-Bren's injectable breast cancer phase III trial completed the first patient enrollment

Zhitong Finance App News, Baili Tianheng (688506.SH) announced that the first phase III randomized controlled clinical trial of the innovative biopharmaceutical T-Bren (HER2 ADC) combined with pertuzumab compared docetaxel plus carboplatin+trastuzumab plus pertuzumab in the new adjuvant treatment for HER2-positive breast cancer, has recently completed the first case of subjects enrolled.

T-Bren (BL-M07D1) is an innovative ADC targeting HER2. It has best-in-class (best-in-class) potential and has shown significant anti-tumor efficacy in clinical trials. Recently, a phase III randomized controlled clinical trial of t-Bren combined with pertuzumab compared with docetaxel, carboplatin, trastuzumab, and pertuzumab in a new adjuvant treatment for HER2-positive breast cancer has recently completed the first patient enrollment.

Up to now, T-Bren is conducting 20 clinical trials at home and abroad, including 9 stage III, 1 phase II/III, 4 phase II, 3 phase I/II, and 3 phase I clinical trials, covering first-line and above HER2-positive breast cancer, HER2-positive breast cancer post-operative adjuvant treatment, HER2-positive breast cancer neoadjuvant treatment, HER2-positive breast cancer, HER2-positive gastric cancer or gastroesophageal adenocarcinoma, HER2-positive gastric cancer or gastroesophageal adenocarcinoma, HER2 mutated non-squamous non-small cell lung cancer, and HER2-positive platinum-containing biliary cancer lung cancer, digestive tract tumors, Multiple indications such as urinary system tumors and gynecological tumors.